All In Biotech

Drug Trial Radar · NCT00242801

Iressa vs Best Supportive Care - 2nd/3rd Line Survival Study

A Double Blind,Placebo Controlled,Parallel Group,Multicentre,Randomised,Phase Iii Survival Study Comparing ZD1839 (IRESSA™)(250mg Tablet) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients With Advanced NSCLC Who Have Received One Or Two Prior Chemotherapy Regimens And Are Refractory Or Intolerant To Their Most Recent Regimen

Last checked: Nov 19, 2026Latest source record: Apr 23, 2009 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,692 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,692

Actual

Start

Jul 2003

Primary completion

Not stated

Study completion Apr 2005

Sponsor

Lead sponsor
AstraZenecaAstraZeneca (AZN)
Sponsor type
Industry
First posted
Oct 21, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being carried out to see if adding ZD1839 to other standard supportive care is more effective than standard supportive care alone for the treatment of patients with NSCLC whose disease has recurred after previous chemotherapy treatment.

Conditions

  • NSCLC

Interventions

  • GefitinibDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The primary objective of this study is to compare overall survival for ZD1839 plus best supportive care versus placebo plus best supportive care

Locations

211 sites in 32 countries. Site status is shown where the registry gives one.

  • Research Site

    Bahía Blanca, Argentina

  • Research Site

    Buenos Aires, Argentina

  • Research Site

    La Plata, Argentina

  • Research Site

    Mar del Plata, Argentina

  • Research Site

    Rosario, Argentina

  • Research Site

    Santa Fe, Argentina

  • Research Site

    Capital Federal, Buenos Aires, Argentina

  • Research Site

    Woodville South, Australia

  • Research Site

    Concord, New South Wales, Australia

  • Research Site

    Potts Point, New South Wales, Australia

  • Research Site

    St Leonards, New South Wales, Australia

  • Research Site

    Chermside, Queensland, Australia

  • Research Site

    South Brisbane, Queensland, Australia

  • Research Site

    Ashford, South Australia, Australia

  • Research Site

    Woodville, South Australia, Australia

  • Research Site

    Melbourne, Victoria, Australia

  • Research Site

    Parkville, Victoria, Australia

  • Research Site

    Prahran, Victoria, Australia

  • Research Site

    Wodonga, Victoria, Australia

  • Research Site

    Fortaleza, Ceará, Brazil

  • Research Site

    Belo Horizonte, Minas Gerais, Brazil

  • Research Site

    Rio de Janeiro, Rio de Janeiro, Brazil

  • Research Site

    Porto Alegre, Rio Grande do Sul, Brazil

  • Research Site

    São Paulo, São Paulo, Brazil

  • Research Site

    Sorocaba, São Paulo, Brazil

  • Research Site

    Pleven, Bulgaria

  • Research Site

    Plovdiv, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Stara Zagora, Bulgaria

  • Research Site

    Varna, Bulgaria

  • Research Site

    Veliko Tarnovo, Bulgaria

  • Research Site

    Calgary, Alberta, Canada

  • Research Site

    Edmonton, Alberta, Canada

  • Research Site

    Monoton, New Brunswick, Canada

  • Research Site

    Greater Sudbury, Ontario, Canada

  • Research Site

    Mississauga, Ontario, Canada

  • Research Site

    Newmarket, Ontario, Canada

  • Research Site

    Saint Catherines, Ontario, Canada

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    York, Ontario, Canada

Showing 40 of 211 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.